Prevention of infection caused by Pneumocystis carinii in transplant recipients

Clinical Infectious Diseases

Volumn 33, Issue 8, 2001, Pages 1397-1405

  Fishman, J A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

DRUG TOLERANCE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; ORGAN TRANSPLANTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ORGAN TRANSPLANTATION; PNEUMOCYSTIS; PNEUMOCYSTIS INFECTIONS;

EID: 0035887676     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323129     Document Type: Review

References (111)

1. Pneumocystis carinii is resistant to imidazole antifungal agents
2. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor
3. New rapid method for the study of Pneumocystis carinii interaction with alveolar macrophages
4. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice
5. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors
6. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329
7. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat
8. Pneumocystis carinii uses a functional cdc13 B-type cyclin complex during its life cycle
9. Phytosterols are present in Pneumocystis carinii
10. Genetic variation in Pneumocystis carinii isolates from different geographic regions: Implications for transmission
11. Prevalence of various Pneumocystis carinii sp. f. hominis types in different geographical locations
12. Genetic diversity in human-derived Pneumocystis carinii isolates from four geographical locations shown by analysis of mitochondrial rRNA gene sequences
13. Geographic variation in the humoral response to Pneumocystis carinii
14. Pneumocystis carinii: What is it, exactly?
15. The genome of Pneumocystis carinii
16. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene
17. Phylogenetic association of Pneumocystis carinii with the 'Rhizopoda/Myxomycota/Zygomycota group' indicated by comparison of 5S ribosomal RNA sequences
18. Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii
19. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model
20. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells
21. Targeting a Pneumocystis carinii group I intron with methylphosphonate oligonucleotides: Backbone charge is not required for binding or reactivity
22. Characterization of the rRNA-encoding genes and transcripts, and a group-I self-splicing intron in Pneumocystis carinii
23. Inhibition of in vitro splicing of a group I intron of Pneumocystis carinii
24. A self-splicing intron in the small subunit rRNA gene of Pneumocystis carinii
25. Cultivation of Pneumocystis carinii in lung-derived cell lines
26. An improved method for the prolonged maintenance of Pneumocystis carinii in vitro
27. A fifteen-year perspective on the in vitro culture of Pneumocystis carinii
28. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii
29. Natural mode of acquisition for de novo infection with Pneumocystis carinii
30. Animal models for Pneumocystis carinii pneumonia
31. Comparison of corticosteroid and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes
32. + cells in resistance to Pneumocystis carinii pneumonia in mice
33. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients
34. Dihydropteroate synthase polymorphisms in Pneumocystis carinii
35. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure
36. A natural source of infection due to Pneumocystis carinii
37. Serial propagation of Pneumocystis carinii in cell line cultures
38. Pneumocystis jiroveci n. sp. from man: Morphology, physiology, and immunology, in relation to pathology
39. Parasitologic and serologic observations of infection with Pneumocystis in humans
40. Serologic responses to Pneumocystis carinii antigens in health and disease
41. Pneumocystis carinii: Improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.)
42. Inoculated mouse model of Pneumocystis carinii infection
43. Clustering of Pneumocystis carinii pneumonia in patients undergoing renal transplantation from living unrelated donors in Iraq and India
44. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: A cluster of Pneumocystis carinii pneumonia in renal transplant recipients
45. Clusters of Pneumocystis carinii pneumonia: Analysis of person-to-person transmission by genotyping
46. Transmission of Pneumocystis carinii from patients to hospital staff
47. Nosocomial transmission of Pneumocystis carinii in renal transplantation
48. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit
49. Typing of Pneumocystis carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA genes
50. - lymphocytes in host defense against Pneumocystis carinii in mice
51. Cellular and humoral immune responses of mice subclinically infected with Pneumocystis carinii
52. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models
53. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
54. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
55. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection
56. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
57. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy
58. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993: An analysis of 78 cases
59. Incidence of Pneumocystis carinii pneumonia after renal transplantation: Impact of immunosuppression
60. Pneumocystis carinii pneumonia in renal transplant recipients
61. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids
62. Pneumocystis carinii pneumonia in renal transplant recipients
63. Cyclosporin and steroids in renal transplantation: Risk of Pneumocystis carinii pneumonia?
64. Cyclosporine therapy and refractory Pneumocystis carinii pneumonia: A potential association
65. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone
66. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients
67. Prevention of infection due to Pneumocystis carinii
68. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole
69. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients
70. Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation - An open clinical trial
71. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation
72. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study
73. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
74. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens
75. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease
76. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia
77. Trimethoprim-sulfamethoxazole therapy for Nocardia infections
78. Antimicrobial susceptibility patterns of Nocardia asteroides
79. Nocardia infection in heart-lung transplant recipients in Alfred Hospital, Melbourne, Australia, 1989-1998
80. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients: A randomized, controlled trial
81. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus
82. Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia
83. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
84. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus
85. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia
86. Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia: Implication of folinic acid
87. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats
88. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death
89. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: A two-year Italian multicentric randomized controlled trial
90. Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation
91. Utility of inhaled pentamidine prophylaxis in lung transplant recipients
92. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone)
93. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfa-methoxazole-intolerant, HIV-infected individuals
94. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: A two-case report and review
95. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation
96. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis
97. Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model
98. In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii
99. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice
100. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS
101. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites
102. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation
103. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia
104. Humoral immunity in experimental Pneumocystis carinii infection. I. Serum and bronchial lavage fluid antibody responses in rats
105. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice
106. Local antibodies against Pneumocystis carinii in bronchoalveolar lavage fluid
107. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice
108. Glycoprotein A is the immunodominant antigen of Pneumocystis carinii in mice following immunization
109. Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia
110. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response
111. Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: Characterization of epitope recognition associated with immunization